Association of typical versus atypical antipsychotics with symptoms and quality of life in schizophrenia

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Fujimaki, Koichiro ^a   Takahashi, Terumichi ^b   Morinobu, Shigeru ^c  

^a PREFECTURAL UNIVERSITY OF HIROSHIMA   (Japan)

^b Mihara Medical Associations Hospital   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BROMPERIDOL; CHLORPROMAZINE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PERICIAZINE; PEROSPIRONE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; COGNITION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE DURATION; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INDUCED EXTRAPYRAMIDAL SYMPTOMS SCALE; DRUG SAFETY; EXTRAPYRAMIDAL SYNDROME; FEMALE; HASEGAWA DEMENTIA SCALE REVISED; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POLYPHARMACY; PSYCHOMETRY; PSYCHOSOCIAL CARE; QUALITY OF LIFE; RATING SCALE; SCHIZOPHRENIA; SCHIZOPHRENIA QUALITY OF LIFE SCALE; SCHIZOPHRENIA QUALITY OF LIFE SCALE TRANSLATED INTO JAPANESE; SYMPTOMATOLOGY;

ANTIPSYCHOTIC AGENTS; BRIEF PSYCHIATRIC RATING SCALE; COGNITION; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHOMETRICS; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84861206966     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037087     Document Type: Article

References (38)

1. Miyamoto A, Hayashi T, Kabeshita Y, Yanagi Y, (2006) Switching from antypsychotic polypharmacy to risperidon monotherapy in chronic schizophrenic inpatients. Japanese Journal of Clinical Psychiatry 9: 65-74.
2. Fukuda M, (2003) The change in first-line antipsychotic treatment for first episode schizophrenic patients at Yamanashi Prefectural Kita Hospital. Japanese Journal of Clinical Psychiatry 6: 403-409.
3. Hirayasu Y, (2004) Switching from high dose poly-antipsychotic therapy to dose-reduced mono-antipsychotic therapy. Japanese Journal of Clinical Psychiatry 7: 59-63.
4. Takashiba T, (2004) Neuroleptics intervention of long-stay patients. Japanese Journal of Clinical Psychiatry 7: 23-29.
5. Malhotra AK, Litman RE, Pickar D, (1993) Adverse effects of antipsychotic drugs. Drug Saf 9: 429-436.
6. Drimer T, Shahal B, Barak Y, (2004) Effects of discontinuation of long-term anticholinergic treatment in elderly schizophrenia patients. Int Clin Psychopharmacol 19: 27-29.
7. Little JT, Johnson DN, Minichiello M, Weingartner H, Sunderland T, (1998) Combined nicotinic and muscarinic blockade in elderly normal volunteers: cognitive, behavioral, and physiologic responses. Neuropsychopharmacology 19: 60-69.
8. Mizusawa H, (1998) Anticholinergic drugs and cognitive functions. Intern Med 37: 493-494.
9. Zemishlany Z, Davidson M, Jaff S, McQueeney R, (1991) Acute administration of alprazolam has no effect on plasma homovanillic acid concentration in normal subjects. Schizophr Res 5: 81-83.
10. Green MF, (1996) What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153: 321-330.
11. Lee MA, Thompson PA, Meltzer HY, (1994) Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry 55 (Suppl B): 82-87.
12. Sharma T, Hughes C, Soni W, Kumari V, (2003) Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia. Psychopharmacology (Berl) 169: 398-403.
13. Stip E, Lussier I, Babai M, Fabian JL, Link C, (1996) Seroquel and cognitive improvement in patients with schizophrenia. Biol Psychiatry 40: 434-435.
14. Bellack AS, Sayers M, Mueser KT, Bennett M, (1994) Evaluation of social problem solving in schizophrenia. J Abnorm Psychol 103: 371-378.
15. Heslegrave RJ, Awad AG, Voruganti LN, (1997) The influence of neurocognitive deficits and symptoms on quality of life in schizophrenia. J Psychiatry Neurosci 22: 235-243.
16. Kurtz MM, Moberg PJ, Ragland JD, Gur RC, Gur RE, (2005) Symptoms versus neurocognitive test performance as predictors of psycho-social status in schizophrenia: a 1- and 4-year prospective study. Schizophr Bull 31: 167-174.
17. Aki H, Tomotake M, Kaneda Y, Iga J, Kinouchi S, et al. (2008) Subjective and objective quality of life, levels of life skills, and their clinical determinants in outpatients with schizophrenia. Psychiatry Res 158: 19-25.
18. Dickerson FB, Ringel NB, Parente F, (1998) Subjective quality of life in out-patients with schizophrenia: clinical and utilization correlates. Acta Psychiatr Scand 98: 124-127.
19. Fitzgerald PB, Williams CL, Corteling N, Filia SL, Brewer K, et al. (2001) Subject and observer-rated quality of life in schizophrenia. Acta Psychiatr Scand 103: 387-392.
20. Huppert JD, Weiss KA, Lim R, Pratt S, Smith TE, (2001) Quality of life in schizophrenia: contributions of anxiety and depression. Schizophr Res 51: 171-180.
21. Reine G, Lancon C, Di Tucci S, Sapin C, Auquier P, (2003) Depression and subjective quality of life in chronic phase schizophrenic patients. Acta Psychiatr Scand 108: 297-303.
22. Tomotake M, Kaneda Y, Iga J, Kinouchi S, Tayoshi S, et al. (2006) Subjective and objective measures of quality of life have different predictors for people with schizophrenia. Psychol Rep 99: 477-487.
23. Norman RM, Malla AK, McLean T, Voruganti LP, Cortese L, et al. (2000) The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the Quality of Life Scale. Acta Psychiatr Scand 102: 303-309.
24. Awad AG, Voruganti LN, Heslegrave RJ, (1997) A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation. Qual Life Res 6: 21-26.
25. Mortimer AM, Al-Agib AO, (2007) Quality of life in schizophrenia on conventional versus atypical antipsychotic medication: a comparative cross-sectional study. Int J Soc Psychiatry 53: 99-107.
26. Ritsner M, Gibel A, Perelroyzen G, Kurs R, Jabarin M, et al. (2004) Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. J Clin Psychopharmacol 24: 582-591.
27. Inagaki A, Inada T, (2006) Dose equivalence of psychotropic drugs. Part 18: dose equivalence of psychotropic drugs: 2006-version. Jpn J Clin Psychopharmacol (in Japanese) 9: 1443-1447.
28. Hasegawa K, (1990) The clinical issues of age-related dementia. Tohoku J Exp Med 161 (Suppl): 29-38.
29. Kolakowska T, (1976) Brief psychiatric rating scale: Glossary and rating instructions Oxford Oxford University Press.
30. Lachar D, Bailley SE, Rhoades HM, Espadas A, Aponte M, et al. (2001) New subscales for an anchored version of the Brief Psychiatric Rating Scale: construction, reliability, and validity in acute psychiatric admissions. Psychol Assess 13: 384-395.
31. Kaneda Y, Imakura A, Fujii A, Ohmori T, (2002) Schizophrenia Quality of Life Scale: validation of the Japanese version. Psychiatry Res 113: 107-113.
32. Wilkinson G, Hesdon B, Wild D, Cookson R, Farina C, et al. (2000) Self-report quality of life measure for people with schizophrenia: the SQLS. Br J Psychiatry 177: 42-46.
33. Inada T, (1996) Evaluation and Diagnosis of Drug-induced Extrapyramidal Symptoms: Commentary on the DIEPSS and Guide to its Usage Tokyo Seiwa Shoten Publishers.
34. Crossley NA, Constante M, McGuire P, Power P, (2010) Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. Br J Psychiatry 196: 434-439.
35. Ritsner M, Modai I, Endicott J, Rivkin O, Nechamkin Y, et al. (2000) Differences in quality of life domains and psychopathologic and psycho-social factors in psychiatric patients. J Clin Psychiatry 61: 880-889; quiz 890.
36. Keefe RS, Silva SG, Perkins DO, Lieberman JA, (1999) The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 25: 201-222.
37. Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, et al. (2004) The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res 68: 283-297.
38. Keefe RS, Poe M, Walker TM, Harvey PD, (2006) The relationship of the Brief Assessment of Cognition in Schizophrenia (BACS) to functional capacity and real-world functional outcome. J Clin Exp Neuropsychol 28: 260-269.